Zejula sNDA submitted to FDA for ovarian, fallopian tube, or primary peritoneal cancer – Tesaro
Tesaro has submitted a supplemental New Drug Application (sNDA) to the FDA for Zejula (niraparib). The application was granted priority review and has an action date of 24 October 2019.